Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
1(50.0%)
N/A
1(50.0%)
2Total
Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07470853Phase 1Recruiting

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

Role: collaborator

NCT02660645Recruiting

Blue Light Cystoscopy With Cysview® Registry

Role: collaborator

NCT04019795Not ApplicableCompleted

Modulated Light Therapy in Participants With Pattern Hair Loss

Role: collaborator

All 3 trials loaded